<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>donor chimerism &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/donor-chimerism/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 27 Oct 2026 23:12:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>donor chimerism &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Blood test duo at three months flags relapse risk after transplants in older leukemia patients</title>
		<link>https://bioengineer.org/blood-test-duo-at-three-months-flags-relapse-risk-after-transplants-in-older-leukemia-patients/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:12:25 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[acute myeloid leukemia]]></category>
		<category><![CDATA[allogeneic stem cell transplantation]]></category>
		<category><![CDATA[clonal hematopoiesis]]></category>
		<category><![CDATA[donor chimerism]]></category>
		<category><![CDATA[donor lymphocyte infusion]]></category>
		<category><![CDATA[measurable residual disease]]></category>
		<category><![CDATA[Myelodysplastic syndromes]]></category>
		<category><![CDATA[next-generation sequencing]]></category>
		<category><![CDATA[older patients]]></category>
		<category><![CDATA[Prognostic biomarkers]]></category>
		<category><![CDATA[reduced-intensity conditioning]]></category>
		<category><![CDATA[relapse risk]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464146</guid>

					<description><![CDATA[A retrospective Korean study found that combining sequencing-based residual disease testing with donor chimerism assessment three months after transplant stratified older AML and MDS patients into groups with two-year survival ranging from 85.6 percent to 13.6 percent.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464146</post-id>	</item>
	</channel>
</rss>
